# A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

Source: https://onco.cc/trials/nct05118789/  
OnCo record `nct05118789` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Zidesamtinib in advanced solid tumours, run by Nuvalent Inc., now recruiting.

## Summary

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) is a phase 1/2 interventional study registered as NCT05118789 by Nuvalent Inc., with 359 participants planned, started 2022-01-04 and due to reach its primary completion in 2027-12-31. Interventions recorded: Zidesamtinib (NVL-520).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05118789
- Phase: 1/2
- Setting: A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)
- Sponsor: Nuvalent Inc.
- Enrolled: 359

## Sources

- ClinicalTrials.gov NCT05118789: https://clinicaltrials.gov/study/NCT05118789

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Zidesamtinib](https://onco.cc/drugs/zidesamtinib/)
- companies: [Nuvalent](https://onco.cc/companies/nuvalent/)

---
JSON: https://onco.cc/api/v1/entities/nct05118789.json